[關(guān)鍵詞]
[摘要]
目的 探討阿托伐他汀對慢性心衰患者NT-proBNP水平及氧化應(yīng)激狀態(tài)的影響。方法 選擇2015年9月—2017年2月非缺血性心臟病慢性心衰患者102例,將所有患者隨機(jī)分為對照組(n=51)和阿托伐他汀組(n=51)。對照組實施常規(guī)抗心衰藥物治療,阿托伐他汀組在常規(guī)抗心衰治療基礎(chǔ)上加用阿托伐他汀治療,20 mg/d。兩組療程均為24周。觀察并比較兩組治療前后三酰甘油(TG)、總膽固醇(TC)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)、NYHA分級、左室射血分?jǐn)?shù)(LVEF)、NT-proBNP、6 min步行距離(6MWT)、超氧化物歧化酶(SOD)、髓過氧化物酶(MPO)、丙二醛(MDA)等指標(biāo)。結(jié)果 阿托伐他汀組治療后TG、TC、LDL-C水平明顯下降,與治療前及對照組比較,差異均有統(tǒng)計學(xué)意義(P<0.05)。兩組患者治療后NT-proBNP水平均有明顯下降,與治療前比較,差異有統(tǒng)計學(xué)意義(P<0.05),但阿托伐他汀組下降幅度優(yōu)于對照組,組間比較差異有統(tǒng)計學(xué)意義(P<0.05)。與同組治療前及對照組比較,阿托伐他汀組治療后SOD明顯增高,MDA、MPO明顯下降,差異均有統(tǒng)計學(xué)意義(P<0.05);而對照組治療前后無明顯變化。結(jié)論 在常規(guī)抗心衰治療的基礎(chǔ)上加用阿托伐他汀,能有效降低CHF患者的NT-proBNP水平和抑制患者的氧化應(yīng)激狀態(tài)。
[Key word]
[Abstract]
Objective To explore the influence of atorvastatin on N-terminal brain natriuretic peptide (NT-proBNP) and oxidative stress in patients with chronic heart failure (CHF). Methods 102 cases of chronic heart failure patients with non-ischaemic heart disease were chosen as chosen as the research objects. The patients were randomly divided into control group (n=51) and atorvastatin group (n=51). The patients were treated with the conventional drugs in control group, and combined with atorvastatin of 20 mg/d in atorvastatin group. All patients were treated for 12 weeks. Triglyceride (TG), total cholesterol (TC), high-density lipoprotein (HDL-C), low density lipoprotein (LDL-C), NYHA classification, left ventricular ejection fraction (LVEF), NT-proBNP, 6 min walking distance (6 MWT), SOD, MPO, MDA were observed and compared before and after treatment in two groups. Results Compared with before treatment and control group, TG, TC, LDL-C decreased obviously after treatment in atorvastatin group, the differences were statistically significant (P < 0.05). NT-proBNP levels decreased significantly after treatment in two groups, compared with that before treatment, the differences were statistically significant (P < 0.05), but the change in atorvastatin group was better than that in control group (P < 0.05). Compared with those before treatment and control group, SOD increased significantly, MDA, MPO decreased significantly after treatment in atorvastatin group, the differences were statistically significant (P < 0.05). The control group had no significant change before and after treatment. Conclusion The conventional anti-heart failure treatment added with atorvastatin could reduce effectively NT-proBNP level and inhibit oxidative stress in CHF patients.
[中圖分類號]
[基金項目]